Summary. Thioridazine (0\ m=. \ 1\ p=n-\ 10\g=m\moll \ m=-\ 1) inhibited shortening of specimens of human vasa deferentia induced by noradrenaline (100 \g=m\moll \ m=-\ 1 ) or high extracellular potassium (136 mmol l \ m=-\ 1). Thioridazine did not inhibit the lengthening response. In Ca2+ -free media with EGTA (0\m=.\5 mmol l \m=-\ 1) similar results were obtained with responses to noradrenaline, but exposure to potassium elicited small contractions that were potentiated by thioridazine. Both shortening and lengthening responses to noradrenaline were antagonized by the \g=a\-adrenoceptor blockers prazosin (1\p=n-\10\g=m\mol l \ m=-\ 1) and phentolamine (1\p=n-\10 \g=m\moll\m=-\1) and by the Ca2+ antagonists verapamil (10 \g=m\moll \ m=-\ 1) and diltiazem (10 \g=m\mol l \ m=-\ 1). Responses to potassium were virtually abolished by the Ca2+ antagonists.
Introduction
Phenothiazine antipsychotic drugs produce their therapeutic action by blocking dopamine D2-receptors (Creese et ai, 1976; Svendsen et ai, 1988) . However, the clinical use of neuroleptic drugs such as thioridazine is associated with some peripheral side effects unrelated to the blockade of dopamine receptors. For example, the sedative and hypotensive action of thioridazine is believed to be caused by the inhibition of ctpadrenoceptors (Peroutka & Snyder, 1980; Gould et ai, 1984) . Its other pharmacological effects include the antagonism of processes that depend on calmodulin (Beitner et ai, 1989) and blockade of histamine, serotonin and muscarinic receptors. The latter is believed to be responsible for the limited extrapyramidal symptoms associated with the use of thioridazine (Gould et ai, 1984; Svendsen et ai, 1988) .
One specific side effect of thioridazine has found some therapeutic application. Thioridazine inhibits sperm emission in patients without affecting normal erection or the sensation of orgasm (Greenberg & Carrillo, 1968; Kotin et ai, 1976) . This effect has been used to inhibit nocturnal emissions and control premature ejaculation (Clein, 1962; Singh, 1963) . It was suggested by Gould et ai (1984) that this effect of thioridazine may be due to the blockade of smooth muscle Ca2 + channels. However, it has been reported that electrically induced responses of the human vas deferens are fairly insensitive to a variety of Ca2+ channel blockers (Fovaeus et ai, 1987; Smith & Bray, 1990) . In an earlier study (Amobi & Smith, 1991) , we found that thioridazine did not affect contractions induced by caffeine or A23187, but induced some rhythmic contractions of the rat vas deferens. Thioridazine only partly inhibited responses to high potassium concentration. Thus, the role of Ca2+ in thioridazine-induced ejaculatory failure remains uncertain. Indeed, there are no reports on the effects of thioridazine on the response of the human vas deferens to its primary transmitter, noradrenaline (Anton & McGrath, 1977; Ratnasooriya et ai, 1979; Bellis et ai, 1982;  "Corresponding author.
thioridazine on the contraction of the human vas deferens induced by exogenous noradrenaline or high extracellular potassium. 
Results
Responses to noradrenaline in normal Krebs' media Responses to noradrenaline (100 pmol 1_1) varied. In 17 of 76 preparations (e.g. Fig. la) there was an initial increase in tension of the tissue (referred to as the shortening response) followed by a decline to less than basal tensions (the lengthening response). In other preparations there was either a shortening (n (Fig. 6a ). The addition of nifedipine (10 pmol l"1) in the continued presence of either verapamil or diltiazem caused no further change in the size of the shortening or lengthening responses induced by noradrenaline (Fig. 6a-c ). (Fig. 7d) .
Activation with high potassium concentration (136 mmol 1 "1 ), after exposure of the tissues for
30-40 min to Ca2
+ -free media containing EGTA (0-5 mmol 1" '), nifedipine and verapamil, elicited small contractions which ranged from 5-21% (mean 7-4 ± 5-9%; = 5) of the initial shortening response in Krebs' media (Fig. 7c ). These were also recorded when the EGTA concentration was raised to 1 mmol I-1 (not shown). They were similar to the persistent response to high potassium concentration found to be resistant to the action of Ca2+ antagonists (see Fig. 5 ). Thioridazine (0-1-10 pmol 1) caused a dose-related potentiation of the response to potassium in Ca2 + -free media ( Fig. 7c and d) . This potentiation persisted after thioridazine was washed out for 30-40 min.
Discussion
Variations in the pattern of response of human vas deferens to direct or indirect muscle stimulation or a-adrenoceptor agonists have been reported by Anton & McGrath (1977) have been ascribed to the contractions of the longitudinal and circular layers of smooth muscle, respectively (Anton & McGrath, 1977; Smith & Bray, 1990 (Murphy et ai, 1983; Thorgeirsson & Rudolph, 1984) and appears to bind to the verapamil site on the Ca2 +-channel (Snyder & Reynolds, 1985) . It has thus been suggested (Gould et ai, 1984) , on the basis of receptor binding and pharmacological studies of rat vas deferens, that the inhibition of ejaculation by thioridazine may be due to the blockade of voltagegated Ca2+ channels. However, the human vas deferens differs from that of rats in several respects (Birmingham, 1968; Anton & McGrath, 1977; Smith & Bray, 1990) . In the present study we found that the effects of thioridazine on the human vas deferens were not matched by diltiazem or verapamil. The lengthening response remained relatively unchanged while the shortening was markedly inhibited or abolished by thioridazine. In contrast, the Ca2+ antagonists reduced both components of the responses. Moreover, in the presence of high doses of diltiazem or verapamil, the residual shortening response to noradrenaline exhibited a biphasic profile; this effect was not observed in the presence of thioridazine.
The persistence of lengthening responses in the presence of thioridazine may be explained by several mechanisms. Thioridazine may penetrate poorly through the tissue because of diffusional potassium. In (c) these effects are compared with those of thioridazine (10 pmol l"1 (from Fig. 4) ). Bars show shortening (upward) and lengthening (downward) responses in the presence of diltiazem (n = 4), verapamil (n = 5) and thioridazine (n = 9). Data are expressed as a percentage of the corresponding component in the drug-free control (*P < 005; **P < 001).
restrictions and thus may not achieve the concentration necessary to block the contraction of the circular smooth muscle layer. Thioridazine may be a less potent Ca2 + antagonist than verapamil or diltiazem. However, these explanations seem unlikely, as the effects of thioridazine were not matched by the actions oflow doses ofdiltiazem. Thus, either the circular muscle exhibits thioridazineinsensitive Ca2+ channels, or the action of thioridazine depends on some other mechanism.
The inhibition by thioridazine of the shortening response induced by noradrenaline does not appear to be caused by the blockade of a-adrenoceptors. This selective action was not replicated by the more conventional a-adrenoceptor blockers, prazosin or phentolamine, or by the prototype phenothiazine, promazine, which reportedly displays an a-adrenoceptor blocking action similar to that of thioridazine (Peroutka & Snyder, 1980) . These drugs abolished both shortening and lengthening responses to noradrenaline. A differential effect could exist if the lengthening response involved the activation of an ,-adrenoceptor subtype (Han et ai, 1987 ) not susceptible to block¬ ade by thioridazine. Nevertheless, the possibility that thioridazine may elicit effects other than the blockade of Oj-adrenoceptors or voltage-gated Ca2+ channels is apparent from the finding that the response to potassium in Ca2 + -free media was enhanced by thioridazine. Smooth muscle may be activated through electro-or pharmaco-mechanical coupling (Somlyo & Somlyo, 1968; Droogmans et ai, 1977; Trapani et ai, 1981 (Mangel et ai, 1982; Mangel, 1984; Amobi & Smith, 1990) which may involve the release of intracellular Ca2 + (Khoyi et ai, 1989) . We have suggested that this is associated with the activation of a calmodulinindependent mechanism of tension production (Amobi & Smith, 1990 . We therefore examined the effects of thioridazine on the responses of human vas deferens in Ca2 + -free media. We have reported previously that contractions produced by agents that released intracellular Ca2+ such as caffeine or A23187 were unaffected by thioridazine (Amobi & Smith, 1991 ). This observation suggests that thioridazine may elicit its effect early in the pathway linking membrane activation to response. Two pharmacological actions of phenothiazines that may be relevant to this include the ability to displace membrane-bound Ca2+ (Kwant&Seeman, 1969; Brostrom etai, 1978) and the inhibition of calmodulin-dependent processes (Janis et ai, 1987; Beitner et ai, 1989 
